BRISTOL MYERS SQUIBB
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2012-02-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 47
- Registration Number
- NCT00764309
- Locations
- ๐บ๐ธ
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
๐บ๐ธBoston University School Of Medicine, Boston, Massachusetts, United States
๐บ๐ธMayo Clinic Arizona, Scottsdale, Arizona, United States
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT00754325
- Locations
- ๐บ๐ธ
Kansas City Cancer Center, Llc., Overland Park, Kansas, United States
๐บ๐ธNorthern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States
๐บ๐ธUs Oncology Research, Inc., Houston, Texas, United States
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1930
- Registration Number
- NCT00744497
- Locations
- ๐บ๐ธ
Maine Center For Cancer Medicine, Scarborough, Maine, United States
๐บ๐ธJackson Oncology Associates, Pllc, Jackson, Mississippi, United States
๐บ๐ธVa Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 141
- Registration Number
- NCT00743938
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธHema/Oncology Assoc. Of Nepa, Dunmore, Pennsylvania, United States
๐บ๐ธCancer Center Of The Carolinas, Greenville, South Carolina, United States
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
- Conditions
- Leukemia, Myeloid, Chronic
- Interventions
- Biological: Ipilimumab
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00732186
- Locations
- ๐บ๐ธ
The University Of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
- Conditions
- Malignant Melanoma
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2010-04-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 92
- Registration Number
- NCT00729950
- Locations
- ๐บ๐ธ
Arizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธUSC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธPiedmont Oncology Specialists, Charlotte, North Carolina, United States
Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma
- Conditions
- Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.
- Interventions
- Biological: MDX-1411
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2010-04-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 34
- Registration Number
- NCT00730652
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
- Conditions
- Metastatic MelanomaMetastatic Castration-resistant Prostrate CancerRenal Cell CarcinomaNon-small Cell Lung Cancer
- Interventions
- Biological: BMS-936558 (MDX-1106)
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 395
- Registration Number
- NCT00730639
- Locations
- ๐บ๐ธ
Pinnacle Oncology Hematology, Scottsdale, Arizona, United States
๐บ๐ธSarah Cannon Research Institute, Nashville, Tennessee, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
Multiple Ascending Dose (MDX1105-01)
- Conditions
- Cancer, Multiple Indications
- Interventions
- Biological: Anti-PDL-1 antibody
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 281
- Registration Number
- NCT00729664
- Locations
- ๐บ๐ธ
Emory University, Atlanta, Georgia, United States
๐บ๐ธOhio State University, Columbus, Ohio, United States
๐บ๐ธThe University Of Texas, Houston, Texas, United States
Drug Interaction Study With a Potential Alzheimer's Disease Compound
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)Drug: BMS-708163 + Cooperstown Cocktail
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2008-11-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT00726726
- Locations
- ๐บ๐ธ
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States